1. Phase II multicentre study of the nitrosourea fotemustine in inoperable squamous cell lung carcinoma
- Author
-
M.L. Cerrina, S. Gouva, T. Le Chevalier, P. Berthaud, J. Berille, A. Riviere, C. Prache, E. Quoix, and C. Zabbe
- Subjects
Adult ,Male ,Nitrosourea ,Pathology ,medicine.medical_specialty ,Lung Neoplasms ,medicine.medical_treatment ,Improved survival ,Antineoplastic Agents ,Squamous cell lung cancer ,Nitrosourea Compounds ,chemistry.chemical_compound ,Organophosphorus Compounds ,medicine ,Humans ,Multicenter Studies as Topic ,Aged ,Chemotherapy ,business.industry ,Melanoma ,Respiratory disease ,Middle Aged ,medicine.disease ,Oncology ,chemistry ,Carcinoma, Squamous Cell ,Cancer research ,Drug Evaluation ,Fotemustine ,Female ,business ,Squamous cell lung carcinoma ,medicine.drug - Abstract
Fotemustine is a new amino acid phosphonate derivative of the nitrosourea group which has yielded good response rates in disseminated malignant melanoma (24.2%). It is associated with a good tolerance and an improved survival time [1, 2]. Other phase II studies have conducted investigations in other tumor types [3, 4]. The present study concerns the results obtained in squamous cell lung cancer
- Published
- 1989